Sagittarius Life Science (ROCO:3205) Total Equity: NT$1,044.8 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:3205 Sagittarius Life Science Corp ROCO:3205
47 GF Score
Price NT$50.60
GF Value NT$17.93
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Sagittarius Life Science Total Equity?

Sagittarius Life Science ROCO:3205 +0.80% 47 Total Equity is NT$1,044.8 Mil as of Dec. 2025. GuruFocus rates ROCO:3205 with a GF Score™ of 47/100 and a GF Value™ of NT$17.93 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Sagittarius Life Science's total equity for the quarter that ended in Dec. 2025 was NT$1,044.8 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Sagittarius Life Science Total Equity Historical Data

* Premium members only.

The historical data trend for Sagittarius Life Science's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sagittarius Life Science Total Equity Chart

Sagittarius Life Science Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 531.71 455.42 526.90 419.76 1,044.80

Sagittarius Life Science Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 419.76 417.05 1,058.18 1,055.90 1,044.80
ROCO:3205
47GF Score
Sagittarius Life Science Corp ROCO:3205
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sagittarius Life Science Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Sagittarius Life Science's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=1071.707-26.907
=1,044.8

Sagittarius Life Science's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=1071.707-26.907
=1,044.8

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of NT$1,044.8 Mil mean?
Sagittarius Life Science (ROCO:3205) has a Total Equity of NT$1,044.8 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Sagittarius Life Science and its competitors.
Is Sagittarius Life Science's Total Equity too high?
Sagittarius Life Science's current Total Equity is NT$1,044.8 Mil. Overall, Sagittarius Life Science has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sagittarius Life Science's Total Equity compare to VRTX and REGN?
Sagittarius Life Science's Total Equity of NT$1,044.8 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Sagittarius Life Science and its competitors. Sagittarius Life Science's current Total Equity is NT$1,044.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sagittarius Life Science stock overvalued right now?
Based on GuruFocus' analysis, Sagittarius Life Science (ROCO:3205) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$17.93, compared to a current price of NT$50.60 — trading 182.2% above its estimated fair value. The current Total Equity is NT$1,044.8 Mil. Sagittarius Life Science's overall GF Score™ is 47/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Sagittarius Life Science (ROCO:3205), the current Total Equity is NT$1,044.8 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sagittarius Life Science (ROCO:3205) Overvalued in 2026?

Based on GuruFocus' analysis, Sagittarius Life Science stock appears to be overvalued. The current stock price of NT$50.60 is trading 182.2% above its estimated GF Value™ of NT$17.93. GuruFocus considers Sagittarius Life Science to be Significantly Overvalued.

Key valuation signals for ROCO:3205:

  • Total Equity: NT$1,044.8 Mil
  • GF Value™: NT$17.93 vs. price of NT$50.60 (182.2% above fair value)
  • GF Score™: 47/100 with 6 warning signs

No single metric tells the full story. See the ROCO:3205 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sagittarius Life Science Business Description

Address No. 3, Park Street, 10-6th Floor, Nangang District, Taipei, TWN
Sagittarius Life Science Corp is a Taiwan-based company engaged in the biotechnology and pharmaceutical sectors. The segment includes: Food and Others, with the majority of revenue from Food.
47GF Score

Get the complete analysis for ROCO:3205

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$50.60
Price
NT$17.93
GF Value